In today’s episode, we had the pleasure of speaking with Shubham Pant, MD, MBBS, about the first-line treatment of patients with metastatic pancreatic cancer. Dr Pant is a professor in the Department of Gastrointestinal (GI) Medical Oncology of the Division of Cancer Medicine, director of Clinical Research, and a professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Dr Pant discussed factors that drive frontline chemotherapy selection for metastatic pancreatic cancer, the role of NALIRIFOX (irinotecan liposome [Onivyde], oxaliplatin, 5-fluorouracil, and leucovorin) in this treatment setting, and how the first-line treatment paradigm may evolve and expand going forward.
OncLive® On Air